Envista Holdings Corp. (NVST)

Over the past six months, Envista Holdings Corp. stock has experienced significant upward trends. In February 2026, the stock reached a new 52-week high after reporting impressive fourth-quarter 2025 financial results, leading to upgrades from William Blair and BofA Securities. Approximately six months prior, the stock gained 8.2% after the company reported strong second-quarter results and raised its full-year financial outlook for 2025. Over the last 12 months, NVST's stock price has increased by 13.98%, with a year-to-date return of 14.21%.

Analysis of Envista Holdings Corp. seasonal charts suggests a "Buy Date of November 8 and a Sell Date of January 27" has historically resulted in a geometric average return of 7.79% above the S&P 500 Total Return Index over the past five years, implying increased investor interest around the end and beginning of the year. However, recent reports indicate a deceleration in Envista's annualized revenue growth, suggesting potential challenges in driving demand for its offerings.

Envista Holdings Corp. operates in the healthcare sector, specifically in the dental products and medical technology industry. Established in 2019 as a spin-off from Danaher Corporation, Envista aims to be a premier global partner for dentists and healthcare professionals. The company operates through two segments: Specialty Products & Technologies, which focuses on dental implant systems and orthodontic products, and Equipment & Consumables, which develops and markets dental equipment and supplies. Envista has a portfolio of over 30 trusted dental brands, including Nobel Biocare, Ormco, and Kerr.

Envista Holdings Corp. has a substantial global reach, serving dental professionals in over 130 countries and operating in more than 120 countries worldwide. Its products and solutions are utilized in an estimated 90% of all dental clinics globally. The company's broad market presence spans North America, Europe, and Asia-Pacific, with a strategic focus on emerging markets.

Envista Holdings Corp. maintains a strong brand reputation, built on a legacy of success and its "Envista Business System" methodology. The company's strong financial performance, strategic initiatives, product innovation, and leadership team refresh have positively impacted its reputation. Envista has focused on accelerating growth, advancing operational excellence, and investing in its people, including significant investments in commercial coverage, clinical education, and new product development.

Major institutional investors hold a significant portion of Envista Holdings Corp. stock, with institutional ownership standing at 100.26%. Key institutional owners include BlackRock Advisors LLC (11%), Vanguard Fiduciary Trust Co. (9.789%), Ariel Investments LLC (7.301%), Eaton Vance Management (6.089%), Fiduciary Trust Company International (5.323%), Franklin Mutual Advisers LLC (4.857%), Harris Associates LP (4.166%), Gates Capital Management, Inc. (3.785%), AllianceBernstein LP (3.709%), and State Street Corp. (3.23%). Individual ownership accounts for 0.76% of the shares.